fonds europen de dveloppement rgional

UGGINNOV: UroGenital and Gastrointestinal INNOVation

“Optimizing the success rate of drug development in urological and digestive diseases”

UGGINNOV is a collaborative project focused on the development of a unique preclinical platform for the testing of new therapies against inflammation and cancer of the bladder, prostate and intestine.

UGGINNOV aims at developing and implementing new preclinical models from “mini-organs” or organoids and Cancer Cell Lines (CCL) to Patient-Derived-Xenograft (PDX) models.

This unique platform will offer to the biotech and pharma industry the opportunity of an optimized screening of biomarkers, new therapies and combinations through a high throughput screening step to selection of drug candidates towards the development of personalized medicine solutions and tools.

It will also support the understanding of the fundamental mechanisms of carcinogenesis and inflammation.

Scientific partners

  • This project is led by Urosphere+ and Urolead in collaboration with the (irsd).
logos partenaires ugginnov

The strength of the present consortium relies on the expertise and long lasting collaboration of the three partners,

  • Uropshere, specialized in preclinical development in urology from pain and inflammation to cancer,
  • Urolead, specialized in PDX models in uro-oncology and
  • The “Institut de Recherche en Santé Digestive” (Irsd), specialized in inflammation and cancer of the intestinal, liver pathologies and urological tracts

Business partners

UGGINNOV was selected among few projects to be funded by the French Region Occitanie and the European Union with a total budget of ~ 1 million euros.

This project strengthens the diversification of Urosphere and Urolead activities through Oncology and Gastroenterology.

UROLEAD has developed key collaborations with Institut Curie to accelerate the characterization of its bladder PDX models.

UROLEAD and the urological department of the Nouvel Hôpital Civil (NHC) of Strasbourg have set up for more than 10 years a strategic partnership for development and histological characterization of urological PDX models. NHC has provided to Urolead more than 900 freshly excised patient tumor samples, after obtention of patient informed consent.

UROLEAD is in close partnership with INSERM for development of RCC PDX models.